News - Boehringer Ingelheim, Financial

Filter

Popular Filters

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

15-04-2014

German family-owned drug major Boehringer Ingelheim today posted financial results for 2013, noting that,…

Boehringer IngelheimFinancialPharmaceutical

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

20-02-2014

US clinical-stage biotech firm Vitae Pharmaceuticals says it has earned a $14 million milestone payment…

BiotechnologyBoehringer IngelheimFinancialNeurologicalResearchVitae Pharmaceuticals

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Boehringer Ingelheim initiates Phase I study with Ablynx nanobody triggering milestone payment

Boehringer Ingelheim initiates Phase I study with Ablynx nanobody triggering milestone payment

29-10-2013

Ablynx says its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical…

AblynxBoehringer IngelheimEuropeFinancialNanobodyNeurologicalPharmaceuticalResearch

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Boehringer Ingelheim remains on growth path, despite difficult scenario

15-08-2013

Family-owned German drug major Boehringer Ingelheim says it grew further in the first half of 2013, despite…

Boehringer IngelheimFinancialPharmaceutical

Boehringer Ingelheim to build biopharma facility in China

07-06-2013

German family-owned drug major Boehringer Ingelheim has signed a strategic alliance agreement and contract…

Asia-PacificBiotechnologyBoehringer IngelheimFinancialPharmaceuticalProductionShanghai Zhangjiang Biotech

Boehringer Ingelheim Venture Fund invests in Eyevensys

15-04-2013

Paris, France-based Eyevensys, a developer of a new process for non-viral gene therapy using electrotransfer…

Boehringer IngelheimEyevensysFinancialMergers & AcquisitionsOphthalmicsPharmaceutical

Boehringer Ingelheim to pay $95 million to resolve False Claims Act allegations in USA

29-10-2012

The US subsidiary of independent German drug major Boehringer Ingelheim has agreed to pay $95 million…

Boehringer IngelheimFinancialLegalMarkets & MarketingNorth AmericaPharmaceutical

Boehringer Ingelheim first-half 2012 sales up 6.8%

15-08-2012

German family-owned drug major Boehringer Ingelheim yesterday reported that, for the first half of 2012,…

Boehringer IngelheimFinancialPharmaceutical

UK academia-pharma collaboration attracts £14.4 million funding

13-05-2012

In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Boehringer Ingelheim says it is on growth path, as 2011 sales rise 6.2%

25-04-2012

German family-owned drug major Boehringer Ingelheim yesterday announced its financial results for full-year…

Boehringer IngelheimFinancialPharmaceutical

Promethera raises 23.6 million euros, with backers including Shire and Boehringer

28-03-2012

Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated…

BiotechnologyBoehringer IngelheimFinancialHepaStemNephrology and HepatologyPromethera BiosciencesRegulationShire

Boehringer expands in China; Lundbeckfond ups ALK-Abello stake

15-12-2011

Family-owned German drug major Boehringer Ingelheim says it intends to invest 70 million euros ($91 million)…

Alk-AbelloAsia-PacificBoehringer IngelheimEuropeFinancialLundbeckfondPharmaceutical

Boehringer Ingelheim invests over $350 million in 2011 US expansion projects

17-11-2011

Privately-held German drug major Boehringer Ingelheim says that it has made more than $350 million worth…

Boehringer IngelheimFinancialNorth AmericaPharmaceuticalResearch

Boehringer Ingelheim first-half 2011 sales rise 2.6%, but up 12% in emerging markets

10-08-2011

Independent German drug major Boehringer Ingelheim has reported sales of 6.4 billion euros ($9.08 billion)…

Boehringer IngelheimFinancialPharmaceutical

AIDS drugmakers’ charity programs fail patients, yet provide millions in tax breaks to industry, AHF accuses, but applauds Boehringer

03-08-2011

The USA-based AIDS Healthcare Foundation (AHF) is, in its own words, “blowing the whistle”…

Boehringer IngelheimFinancialGilead SciencesNorth AmericaPharmaceuticalPricing

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top